Masimo Co. (NASDAQ:MASI) Given Average Rating of “Moderate Buy” by Analysts

Masimo Co. (NASDAQ:MASI) has received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $163.67.

Several brokerages have recently weighed in on MASI. Wells Fargo & Company upped their price objective on Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Piper Sandler upped their price objective on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective for the company in a report on Wednesday, November 6th. BTIG Research upped their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th.

Masimo Trading Down 0.5 %

NASDAQ:MASI opened at $161.63 on Tuesday. Masimo has a 1 year low of $86.94 and a 1 year high of $173.90. The stock has a market cap of $8.65 billion, a price-to-earnings ratio of 111.47 and a beta of 0.97. The business has a fifty day moving average of $133.52 and a 200-day moving average of $125.93. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.15 and a current ratio of 2.01.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.63 earnings per share. Equities analysts predict that Masimo will post 4.04 earnings per share for the current year.

Institutional Investors Weigh In On Masimo

Several hedge funds have recently bought and sold shares of the business. Farallon Capital Management LLC lifted its stake in Masimo by 13.6% in the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after acquiring an additional 177,914 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after acquiring an additional 360,497 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in Masimo by 107.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock worth $85,347,000 after acquiring an additional 351,523 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Masimo by 45.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock worth $66,201,000 after acquiring an additional 165,257 shares in the last quarter. Finally, Bamco Inc. NY purchased a new stake in Masimo in the 1st quarter worth about $50,781,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.